Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
Company Overview
GRI Bio Inc is a clinical-stage biotech company dedicated to discovering, developing, and commercializing novel therapeutics that target the complex mechanisms of dysregulated immune responses. With a strong emphasis on biotech innovation, immunotherapy, and clinical-stage drug development, the company is redefining approaches for treating inflammatory, fibrotic, and autoimmune disorders. The company’s core expertise lies in harnessing the power of natural killer T (NKT) cells, which serve as a critical link between the innate and adaptive immune systems. By modulating these unique cells, GRI Bio aims to restore immune homeostasis and mitigate the damaging inflammatory responses underlying several severe medical conditions.
Scientific and Clinical Approach
At the heart of GRI Bio’s research is the distinct role of NKT cells. These cells exhibit properties of both natural killer cells and T cells to orchestrate and regulate the immune response. In particular, type I NKT cells are known to trigger inflammatory cascades that contribute substantially to cellular and tissue injury. GRI Bio’s lead candidate, GRI-0621, is a small molecule designed as an inhibitor of type I NKT cell activity. This oral therapeutic formulation is engineered to counteract the excessive inflammatory response associated with diseases such as acute liver failure, while also offering promising applications for conditions like psoriasis and acne.
In addition to GRI-0621, the company is advancing GRI-0803, a novel oral agonist targeting type II NKT cells. By influencing this alternative pathway, GRI-0803 holds the potential to offer therapeutic relief for a range of autoimmune and inflammatory conditions. The strategic development of these products underscores GRI Bio’s commitment to offering innovative treatments that address high unmet needs in the market.
Pipeline and Therapeutic Portfolio
GRI Bio’s pipeline is thoughtfully designed to cater to multiple therapeutic areas while leveraging a unified scientific platform centered on NKT cell biology. The company’s dual approach involves:
- GRI-0621: An inhibitor of type I NKT cells, formulated as a novel oral therapeutic aimed primarily at acute liver failure. Its mechanism of action focuses on dampening the inflammatory processes that lead to hepatic injury. Additionally, the formulation explores topical applications for the treatment of dermatological conditions such as psoriasis and acne.
- GRI-0803: An innovative oral agonist that modulates type II NKT cells, thereby offering a potential therapeutic avenue for various autoimmune disorders. This candidate is designed to recalibrate immune responses where dysregulation plays a central role in disease pathology.
Market Position and Competitive Landscape
Within the evolving biotech sector, GRI Bio distinguishes itself through the targeted modulation of NKT cells—a mechanism that addresses the underlying causes of inflammatory and autoimmune diseases rather than merely managing symptoms. The company’s strategic focus on developing oral therapeutic options not only facilitates ease of administration compared to parenteral therapies but also enhances patient compliance. In an industry where treatment options for conditions like acute liver failure and certain autoimmune diseases remain limited, GRI Bio’s scientific approach represents a novel pathway that may transform traditional treatment paradigms.
GRI Bio’s emphasis on reestablishing immune homeostasis by directly influencing key cellular pathways positions it uniquely against competitors that primarily focus on symptomatic relief. Its rigorous clinical evaluation and commitment to scientific excellence underscore the company’s potential as a niche innovator within a competitive and rapidly advancing market environment.
Core Value Proposition and Industry Impact
GRI Bio offers a well-defined value proposition centered on precision immunomodulation. By targeting specific subtypes of NKT cells, its therapies are designed to intervene in the early stages of inflammatory cascades, providing a more precise and potentially safer treatment modality than conventional anti-inflammatory drugs. The company’s extensive research into the dual roles of NKT cells has led to actionable insights that bridge basic scientific discoveries with clinical applications.
This detailed understanding of immune regulation not only fuels its product development but also establishes GRI Bio as an entity with deep scientific expertise and a forward-thinking clinical strategy. Its programs underscore the potential benefits of combining rigorous preclinical research with the strategic development of therapies that cater to complex, multifactorial diseases.
Scientific Rigor and Operational Excellence
Every stage of GRI Bio’s development is underpinned by a commitment to scientific rigor and operational excellence. The company maintains a robust research framework that incorporates both in vitro studies and diverse animal models to validate its therapeutic approach. For example, its exploration of pulmonary fibrosis using established murine models underlines a commitment to understanding disease mechanisms in multiple biological contexts. This multifaceted approach aids in de-risking its clinical candidates and reinforces the company’s reputation for meticulous research planning and execution.
Furthermore, GRI Bio’s operational protocols are designed with a focus on safety, efficacy, and regulatory compliance. This careful calibration of scientific innovation with operational diligence enhances investor confidence and solidifies the company’s standing as a committed participant in the biotech sector.
Conclusion
In summary, GRI Bio Inc stands out as a clinical-stage biotech entity that is deeply invested in the discovery and development of NKT cell-targeted therapies. Its pioneering work in modulating immune responses through agents like GRI-0621 and GRI-0803 reflects both an innovative scientific approach and a sound business strategy geared toward addressing unmet medical needs. With a comprehensive research framework, an expansive therapeutic pipeline, and a clear focus on precision immunomodulation, GRI Bio continues to build an informational foundation that is as robust as it is forward-thinking, positioning the company as a significant contributor to the field of precision medicine and immunotherapy.
This detailed overview provides investors and industry professionals with a clear understanding of GRI Bio’s operational focus, scientific methodologies, and market positioning, all while ensuring that the content remains evergreen and relevant for years to come.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, has announced regaining compliance with Nasdaq's minimum bid price rule. The company received official notice from Nasdaq on March 10, 2025, confirming its compliance with Listing Rule 5550(a)(2).
GRI Bio (NASDAQ: GRI) has announced a 1-for-17 reverse stock split, effective February 21, 2025, at 4:01 p.m. Eastern Time. The company's common stock will begin trading on a split-adjusted basis on February 24, 2025, under the same ticker symbol 'GRI' but with a new CUSIP number.
The reverse split aims to increase the per share trading price to regain compliance with Nasdaq's minimum bid price requirement. The split will reduce outstanding shares from approximately 8,933,366 to 525,492. Proportional adjustments will be made to exercise and conversion prices of outstanding stock options, warrants, and convertible securities.
No fractional shares will be issued; stockholders will receive cash payments for fractional shares. Stockholders with electronic book-entry shares require no action, while those holding physical certificates will receive instructions from Broadridge Corporate Issuers Solutions for exchanging certificates.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the Virtual Investor "Top 5 for '25" On-Demand Conference. The company's CEO, Marc Hertz, Ph.D., presented the top five reasons why investors and industry colleagues should watch GRI Bio in 2025. The presentation is available for viewing on the company's website and through the conference platform.
GRI Bio (NASDAQ: GRI) announced that the European Patent Office will issue a patent on January 16, 2025, covering GRI-0803 and its library of 500+ proprietary compounds. The patent, titled 'Oxygenated Amino- or Ammonium-Containing Sulfonic Acid, Phosphonic Acid and Carboxylic Acid Derivatives and Their Medical Use,' includes coverage of GRI-0803, a novel activator of human type 2 NKT cells being developed for autoimmune disorders, particularly systemic lupus erythematosus (SLE).
The company's preclinical studies showed that type 2 NKT activating molecules inhibited both murine and human iNKT cells, with oral administration inhibiting lupus nephritis and improving survival. While GRI Bio is currently focusing on GRI-0621, which is in Phase 2a trials for IPF with interim data expected in Q1 2025, the GRI-0803 program will continue in 2025 pending additional funding.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, has announced its participation in the Virtual Investor Closing Bell Series.
The event will take place on Thursday, December 12th, 2024 at 4:00 PM ET, featuring CEO Marc Hertz, PhD, who will present a corporate overview and business outlook. The session will include a moderated discussion and a live Q&A segment where investors can submit questions.
A live video webcast will be available on the Events page of GRI Bio's website, with a replay accessible for 90 days following the event.
GRI Bio presented positive preclinical data for GRI-0621, its lead program targeting Idiopathic Pulmonary Fibrosis (IPF), at the 8th Annual Antifibrotic Drug Development Summit. The data showed that GRI-0621 reduces inflammation and fibrotic drivers in IPF. Key findings demonstrated increased iNKT cell activity correlating with fibrosis progression, while GRI-0621 administration inhibited pro-inflammatory cytokines and decreased neutrophil accumulation. The company is currently conducting a Phase 2a clinical trial for IPF treatment, with interim data expected in Q1 2025 and topline results in Q2 2025.
GRI Bio reported Q3 2024 financial results and progress on GRI-0621, its lead program for Idiopathic Pulmonary Fibrosis (IPF). The company raised $13.9 million in gross proceeds since early 2024, extending cash runway into mid-Q1 2025. Net loss was $6.3 million for the nine months ended September 30, 2024, with R&D expenses at $2.9 million and G&A expenses at $3.3 million. Cash position stands at $4.7 million. The company expects interim data from Phase 2a biomarker study in Q1 2025 and topline results in Q2 2025.
GRI Bio (NASDAQ: GRI) has announced definitive agreements for the exercise of existing warrants to purchase 762,236 shares of common stock at a reduced price of $1.00 per share, down from the original $14.30. In exchange, the company will issue new unregistered Series D-1 and D-2 warrants, each for up to 762,236 shares at $1.00 per share. The D-1 warrants have a 5-year term, while D-2 warrants have an 18-month term.
The offering, expected to close around October 22, 2024, is anticipated to generate gross proceeds of approximately $0.8 million. H.C. Wainwright & Co. is acting as the exclusive placement agent. GRI Bio plans to use the net proceeds for working capital and general corporate purposes. The new warrants are being offered in a private placement and have not been registered under the Securities Act.
GRI Bio (NASDAQ: GRI) presented positive preclinical data for its lead program GRI-0621 at the 22nd International Colloquium on Lung and Airway Fibrosis. The data demonstrated GRI-0621's ability to inhibit invariant Natural Killer T (iNKT) cell activity and reduce inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF).
Key findings include:
- Increased expression of pro-fibrotic factors in IPF patients
- Increased IFN-γ producing NKT cells in IPF patients
- GRI-0621 treatment improved inflammatory, fibrotic, and pathological features in a bleomycin model of pulmonary fibrosis
GRI Bio is currently conducting a Phase 2a biomarker study of GRI-0621 in IPF patients, with interim data expected in Q4 2024 and topline results in Q1 2025.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF 2024). The event will take place from October 12-16, 2024, in Athens, Greece.
The company's abstract has been accepted for a poster presentation titled "Involvement of Type 1 Invariant Natural Killer T Cells in Driving Lung Fibrosis." Dr. Vipin Kumar Chaturvedi, GRI Bio's Chief Scientific Officer, will present the poster (Number PP 184) on Tuesday, October 15, 2024, from 3:30 PM to 5:00 PM EEST.
This presentation highlights GRI Bio's ongoing research in the field of lung fibrosis and demonstrates the company's commitment to advancing its innovative pipeline of NKT cell modulators for treating various diseases.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
What is the primary focus of GRI Bio?
How do GRI Bio's therapies work?
What diseases are targeted by GRI Bio's products?
How does GRI-0621 function in treating liver disease?
What distinguishes GRI Bio from its competitors?
What potential does GRI-0803 have in addressing autoimmune disorders?
Does GRI Bio explore therapies beyond liver diseases?
How does the company ensure scientific and operational quality?
